title: Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression.
abstract: OBJECTIVE
  To prospectively determine if estrogen receptor (ER)-negative human epidermal growth factor receptor type 2 (HER2)-positive and ER-negative HER2-negative breast cancers have distinguishing clinical and imaging features with use of retrospectively identified patients and tissue samples.
  
  
  METHODS
  This HIPAA-compliant study was institutional review board approved. Informed consent was obtained from living patients and waived for deceased patients. Mean patient age at diagnosis was 53 years (range, 31-84 years). Clinical history; histopathologic, mammographic, and breast sonographic findings; and HER2 status as determined with immunohistochemistry or fluorescent in situ hybridization were evaluated in 56 women with ER-negative breast cancer. Imaging appearances and clinicopathologic characteristics were correlated with tumor HER2 status. P < .05 indicated a significant difference.
  
  
  RESULTS
  Lesion margins on mammograms (P = .028) and sonograms (P = .023), calcifications on mammograms (P = .003), and clinical cancer stage at diagnosis (P = .029) were significantly associated with HER2 status. In contrast to ER-negative HER2-negative tumors, ER-negative HER2-positive tumors were more likely to have spiculated margins (56% vs 15%), be associated with calcifications (65% vs 21%), and be detected at a higher cancer stage (74% vs 57%).
  
  
  CONCLUSIONS
  Biologic diversity of cancers may manifest in imaging characteristics, and, conversely, studying the range of imaging features of cancers may help refine current molecular phenotypes.
authors.affiliation: Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305-5494, USA.
authors.forename: Yingbing
authors.initials: Y
authors.lastname: Wang
authors.forename: Debra M
authors.initials: DM
authors.lastname: Ikeda
authors.forename: Balasubramanian
authors.initials: B
authors.lastname: Narasimhan
authors.forename: Teri A
authors.initials: TA
authors.lastname: Longacre
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Bleicher
authors.forename: Sunita
authors.initials: S
authors.lastname: Pal
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Jackman
authors.forename: Stefanie S
authors.initials: SS
authors.lastname: Jeffrey
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000378:metabolism*; D002114:Calcinosis / Q000145:classification / Q000175:diagnosis* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008327:Mammography / Q000379:methods*; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human